Skip to main content
Log in

NSAID-Related Psychiatric Adverse Events

Who is at Risk?

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

NSAIDs are frequently used in clinical practice and they account for approximately 5–10% of all drug prescriptions. NSAID use has been associated with a risk of adverse events, which have a relevant impact on morbidity and mortality and account for a substantial increment of healthcare costs. Less common, but clinically relevant, adverse events associated with NSAID use are the impairment of the CNS and, particularly, the appearance of psychiatric symptoms. These symptoms include changes in cognition, mood state and even precipitation or exacerbation of pre-existing psychiatric disorders. This article aims to review the medical literature on published reports of NSAID-related psychiatric adverse events, identify risk factors for these events and describe mechanisms potentially involved in their onset.

We identified 27 reports with data on 453 cases of NSAID-related psychiatric adverse events. Data suggest that individuals who may be particularly susceptible to such events include patients with a history of psychiatric illness and possibly parturients. Indometacin and selective cyclo-oxygenase (COX)-2 inhibitors were the most frequently reported culprit drugs; however, whether this reflects an increased incidence with these drugs compared with other NSAIDs or factors such as usage or reporting patterns is unknown.

A possible explanation for the psychiatric effect of NSAIDs resides in the modulation of central neurotransmission by prostaglandins, the synthesis of which is inhibited by NSAIDs. COX-2 is a key enzyme in this process since its activity is localised in distal dendrites and dendritic spines, which are cellular specialisations involved in synaptic signalling. Dopamine is considered the most relevant neurotransmitter involved in this phenomenon.

Psychiatric symptoms are a rare but relevant complication of NSAID use. This effect is probably a consequence of impairment in neurotransmission modulated by prostaglandins when NSAIDs are used by susceptible individuals. These drugs should be used with caution in high-risk individuals with pre-existing psychiatric illness, and caution may also be advisable in the postpartum period. To date, reports of NSAID-related psychiatric adverse events have most commonly involved indometacin and selective COX-2 inhibitors. Prescribers should consider warning patients of the possibility of an acute neuropsychiatric event when traditional NSAIDs or selective COX-2 inhibitors are prescribed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am J Med 2001 Jan 8; 110(1A): 4S–7S

    Article  PubMed  CAS  Google Scholar 

  2. Paulose-Ram R, Hirsch R, Dillon C, et al. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf 2003 Jun; 12(4): 315–26

    Article  PubMed  Google Scholar 

  3. Lipsky PE. The role of COX-2-specific inhibitors in clinical practice. Am J Med 2001 Feb 19; 110 Suppl. 3A: 1S–2S

    Article  PubMed  Google Scholar 

  4. Vane JR, Botting RM. Mechanism of action of antiinflammatory drugs. Int J Tissue React 1998; 20(1): 3–15

    PubMed  CAS  Google Scholar 

  5. Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995 Mar 30; 332(13): 848–54

    Article  PubMed  CAS  Google Scholar 

  6. Langman MJ, Cheng KK, Gilman EA, et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000 Jun 17; 320(7250): 1642–6

    Article  PubMed  CAS  Google Scholar 

  7. Onder G, Penninx BW, Landi F, et al. Depression and adverse drug reactions among hospitalized older adults. Arch Intern Med 2003 Feb 10; 163(3): 301–5

    Article  PubMed  Google Scholar 

  8. Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 2002 Dec; 50(12): 1962–8

    Article  PubMed  Google Scholar 

  9. Rodriguez-Monguio R, Otero M, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics 2003; 21(9): 623–50

    Article  PubMed  Google Scholar 

  10. Johnson AG, Day RO. The problems and pitfalls of NSAID therapy in the elderly (Pt I). Drugs Aging 1991 Mar; 1(2): 130–43

    Article  PubMed  CAS  Google Scholar 

  11. Pilotto A, Franceschi M, Leandro G, et al. NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Drugs Aging 2003; 20(9): 701–10

    Article  PubMed  CAS  Google Scholar 

  12. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000 Mar 1; 151(5): 488–96

    Article  PubMed  CAS  Google Scholar 

  13. Bleumink GS, Feenstra J, Sturkenboom MC, et al. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 2003; 63(6): 525–34

    Article  PubMed  CAS  Google Scholar 

  14. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001 Aug 22–29; 286(8): 954–9

    Article  PubMed  CAS  Google Scholar 

  15. Jiang HK, Chang DM. Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports. Clin Rheumatol 1999; 18(4): 339–45

    Article  PubMed  CAS  Google Scholar 

  16. Clark DW, Ghose K. Neuropsychiatric reactions to nonsteroidal anti-inflammatory drugs (NSAIDs): the New Zealand experience. Drug Saf 1992 Nov–Dec; 7(6): 460–5

    Article  PubMed  CAS  Google Scholar 

  17. Clunie M, Crone LA, Klassen L, et al. Psychiatric side effects of indomethacin in parturients. Can J Anaesth 2003 Jun–Jul; 50(6): 586–8

    Article  PubMed  Google Scholar 

  18. Celecoxib (Celebrex™): 1 year later. Canadian ADR Newsletter 2000 Apr; 10(2): 1–3

    Google Scholar 

  19. Coulter D. Acute psychiatric reactions with cox-2 inhibitors. Prescriber Update 2002 Jul; 23(2): 21

    Google Scholar 

  20. Acute neuropsychiatric events with celecoxib and rofecoxib. Aust Adv Drug Reactions Bull 2003; 22(1): 3

    Google Scholar 

  21. Boyle AC. Indomethacin and peptic ulcer [letter]. BMJ 1965 May 1; 5443: 1191

    Article  Google Scholar 

  22. Rothermich NO. An extended study of indomethacin. I: clinical pharmacology. JAMA 1966 Feb 14; 195(7): 531–6

    CAS  Google Scholar 

  23. Thompson M, Percy JS. Further experience with indomethacin in the treatment of rheumatic disorders. BMJ 1966 Jan 8; 5479: 80–3

    Article  Google Scholar 

  24. Carney MW. Paranoid psychosis with indomethacin. BMJ 1977 Oct 15; 2(6093): 994–5

    Article  PubMed  CAS  Google Scholar 

  25. Gotz V. Paranoid psychosis with indomethacin [letter]. BMJ 1978 Jan 7; 1(6104): 49

    Article  PubMed  CAS  Google Scholar 

  26. Kruis R, Barger R. Paranoid psychosis with sulindac [letter]. JAMA 1980 Apr 11; 243(14): 1420

    Article  PubMed  CAS  Google Scholar 

  27. Thornton TL. Delirium associated with sulindac [letter]. JAMA 1980 Apr 25; 243(16): 1630–1

    Article  PubMed  CAS  Google Scholar 

  28. Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum 1982 Aug; 25(8): 1013–5

    Article  PubMed  CAS  Google Scholar 

  29. Griffith JD, Smith CH, Smith RC. Paranoid psychosis in a patient receiving ibuprofen, a prostaglandin synthesis inhibitor: case report. J Clin Psychiatry 1982 Dec; 43(12): 499–500

    PubMed  CAS  Google Scholar 

  30. Schwartz JI, Moura RJ. Severe depersonalization and anxiety associated with indomethacin. South Med J 1983 May; 76(5): 679–80

    Article  PubMed  CAS  Google Scholar 

  31. Sotsky SM, Tossell JW. Tolmetin induction of mania. Psychosomatics 1984 Aug; 25(8): 626–8

    Article  PubMed  CAS  Google Scholar 

  32. Browning CH. Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. Int J Psychiatry Med 1996; 26(1): 25–34

    Article  PubMed  CAS  Google Scholar 

  33. Mallet L, Kuyumjian J. Indomethacin-induced behavioral changes in an elderly patient with dementia. Ann Pharmacother 1998 Feb; 32(2): 201–3

    Article  PubMed  CAS  Google Scholar 

  34. Ritter A, Eskin B. Ibuprofen overdose presenting with severe agitation and hypothermia. Am J Emerg Med 1998 Sep; 16(5): 549–50

    Article  PubMed  CAS  Google Scholar 

  35. Nassif JM, Ritter MA. Indomethacin-induced postoperative psychosis. J Arthroplasty 1999 Sep; 14(6): 769–70

    Article  PubMed  CAS  Google Scholar 

  36. Tharumaratnam D, Bashford S, Khan SA. Indomethacin induced psychosis. Postgrad Med J 2000 Nov; 76(901): 736–7

    Article  PubMed  CAS  Google Scholar 

  37. Lantz MS, Giambanco V. Acute onset of auditory hallucinations after initiation of celecoxib therapy. Am J Psychiatry 2000 Jun; 157(6): 1022–3

    Article  PubMed  CAS  Google Scholar 

  38. Macknight C, Rojas-Fernandez CH. Celecoxib- and rofecoxibinduced delirium. J Neuropsychiatry Clin Neurosci 2001 Spring; 13(2): 305–6

    Article  PubMed  CAS  Google Scholar 

  39. Katz N, Zemishlany Z, Weizman A. Ibuprofen and psychotic exacerbation. Am J Psychiatry 2002 Sep 1; 159(9): 1606–7

    Article  PubMed  Google Scholar 

  40. Bernstein AL, Werlin A. Pseudodementia associated with use of ibuprofen. Ann Pharmacother 2003 Jan; 37(1): 80–2

    Article  PubMed  Google Scholar 

  41. Eser D, Zwanzger P, Rupprecht R. Carbamazepine treatment of adverse psychiatric effects after treatment with the nonsteroidal anti-inflammatory drug piroxicam. J Clin Psychiatry 2003 Jul; 64(7): 852–4

    Article  PubMed  Google Scholar 

  42. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97–120

    Article  PubMed  CAS  Google Scholar 

  43. Kaufmann WE, Andreasson KI, Isakson PC, et al. Cyclooxygenases and the central nervous system. Prostaglandins 1997 Sep; 54(3): 601–24

    Article  PubMed  CAS  Google Scholar 

  44. Horrobin DF. The roles of prostaglandins and prolactin in depression, mania and schizophrenia. Postgrad Med J 1977; 53 Suppl. 4: 160–5

    PubMed  CAS  Google Scholar 

  45. Horrobin DF, Manku MS. Possible role of prostaglandin E1 in the affective disorders and in alcoholism. BMJ 1980 Jun 7; 280(6228): 1363–6

    Article  PubMed  CAS  Google Scholar 

  46. Laruelle M, Abi-Dargham A, Gil R, et al. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999 Jul 1; 46(1): 56–72

    Article  PubMed  CAS  Google Scholar 

  47. Ellison G. Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Res Brain Res Rev 1994 May; 19(2): 223–39

    Article  PubMed  CAS  Google Scholar 

  48. Ross BM, Brooks RJ, Lee M, et al. Cyclooxygenase inhibitor modulation of dopamine-related behaviours. Eur J Pharmacol 2002 Aug 23; 450(2): 141–51

    Article  PubMed  CAS  Google Scholar 

  49. van Kammen DP, Yao JK, Goetz K. Polyunsaturated fatty acids, prostaglandins, and schizophrenia. Ann N Y Acad Sci 1989; 559: 411–23

    Article  PubMed  Google Scholar 

  50. Kaiya H, Imai H, Muramatsu Y, et al. Platelet aggregation response in schizophrenia and prostaglandin El. Psychiatry Res 1983 Aug; 9(4): 309–18

    Article  PubMed  CAS  Google Scholar 

  51. Vaddadi K. Dyskinesias and their treatment with essential fatty acids: a review. Prostaglandins Leukot Essent Fatty Acids 1996 Aug; 55(1–2): 89–94

    Article  PubMed  CAS  Google Scholar 

  52. Kanof PD, Davidson M, Johns CA, et al. Clinical correlates of platelet prostaglandin receptor subsensitivity in schizophrenia. Am J Psychiatry 1987 Dec; 144(12): 1556–60

    PubMed  CAS  Google Scholar 

  53. Vinogradov S, Csernansky JG. Postpartum psychosis with abnormal movements: dopamine supersensitivity unmasked by withdrawal of endogenous estrogens? J Clin Psychiatry 1990 Sep; 51(9): 365–6

    PubMed  CAS  Google Scholar 

  54. Fink G, Sumner BE, Rosie R, et al. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol 1996 Jun; 16(3): 325–44

    Article  PubMed  CAS  Google Scholar 

  55. Haag M. Essential fatty acids and the brain. Can J Psychiatry 2003 Apr; 48(3): 195–203

    PubMed  Google Scholar 

  56. Hoppmann RA, Peden JG, Ober SK. Central nervous system side effects of nonsteroidal anti-inflammatory drugs: aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med 1991 Jul; 151(7): 1309–13

    Article  PubMed  CAS  Google Scholar 

  57. Scideman P, von Arbin M. Cerebral blood flow and indomethacin drug levels in subjects with and without central nervous side effects. Br J Clin Pharmacol 1991 Apr; 31(4): 429–32

    Article  Google Scholar 

  58. Onder G, Gambassi G, Scales CJ, et al. Adverse drug reactions and cognitive function among hospitalized older adults. Eur J Clin Pharmacol 2002 Aug; 58(5): 371–7

    Article  PubMed  Google Scholar 

  59. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997 Jul 28; 157(14): 1531–6

    Article  PubMed  CAS  Google Scholar 

  60. Onder G, Landi F, Cesari M, et al. Inappropriate medication use among hospitalized older adults in Italy: results from the Italian Group of Pharmacoepidemiology in the Elderly. Eur J Clin Pharmacol 2003 Jun; 59(2): 157–62

    PubMed  Google Scholar 

  61. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999 Jun 22; 96(13): 7563–8

    Article  PubMed  CAS  Google Scholar 

  62. Muller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002 Jun; 159(6): 1029–34

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors have no conflicts of interest that are directly relevant to the content of this review. The work of Dr Onder was sponsored by the Italian Ministry of Health.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Graziano Onder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Onder, G., Pellicciotti, F., Gambassi, G. et al. NSAID-Related Psychiatric Adverse Events. Drugs 64, 2619–2627 (2004). https://doi.org/10.2165/00003495-200464230-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464230-00001

Keywords

Navigation